tiprankstipranks
PTC Therapeutics price target raised to $70 from $52 at Baird
The Fly

PTC Therapeutics price target raised to $70 from $52 at Baird

Baird analyst Joel Beatty raised the firm’s price target on PTC Therapeutics (PTCT) to $70 from $52 and keeps an Outperform rating on the shares. The firm raised its target as they believe the value of the new Huntington’s disease collaboration with Novartis (NVS) is not yet fully priced in to the stock.

Don't Miss our Black Friday Offers:

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App